Purpose: To present a retrospective analysis of the efficacy, toxicity, and quality of life (QoL) of patients treated with OARExtreme-sparing stereotactic body radiotherapy (SBRT) in previously-irradiated head and neck cancer.Materials/Methods: From 11/2012 to 7/2015, 60 patients with in-field recurrence of head and neck cancer underwent re-irradiation with SBRT. Retreatment sites included the aerodigestive tract (43%), lateral neck (22%), and skull base (35%). The median prior RT dose was 63.6 Gy with a median time from prior irradiation of 16.5 months. The median volume treated was 61.0 cc. Patients were treated with 40 Gy in the definitive setting or 35 Gy in the post-operative setting in five fractions. Dose constraints to the OARExtreme were calculated with a BED calculator using an alpha/beta ratio of 3 to reduce the risk of late toxicities. QoL data was collected from patients at the time of consultation and at subsequent follow up appointments using the MD Anderson Dysphagia Inventory (MDADI) and Symptom Inventory (MDASI).Results: The 1- and 2- year rates of local, regional, and distant control and overall survival were 79/79, 74/70, 74/71, and 59/45%, respectively. Late grade 3 toxicities were seen in 3% in the group treated to the aerodigestive tract and 1% in the group treated to the skull base. No grade 4 or 5 toxicities were observed. Patients with skull base re-irradiation maintained a stable QoL score after radiation treatment, while patients treated to the aerodigestive tract demonstrated a slight impairment associated with worsening dysphagia, compared to their pretreatment baseline. All groups experienced an increase in xerostomia.Conclusions: OARExtreme-sparing SBRT is able to achieve excellent tumor coverage while protecting the organs at highest risk of re-irradiation-related complications. The potential for lower toxicities and maintained QoL with this treatment makes it a promising option for salvage of recurrent head and neck cancer.SummaryLocal control and overall survival rates for recurrent head and neck cancer remain poor, despite the use of local therapy. In addition, re-irradiation with conventional radiation therapy confers a high rate of grade 3 and higher late toxicities. SBRT appears to improve the therapeutic ratio in this patient population, and treatment planning with a focus on sparing OARExtreme may further decrease the rates of morbidity in these patients.

No abstract

No abstract

To evaluate the clinical feasibility and dosimetric benefits of a novel gantry‐static couch‐motion (GsCM) technique for external beam photon boost treatment of lumpectomy cavity in patients with early‐stage breast cancer in comparison to three‐dimensional conformal radiotherapy (3D‐CRT), wedge pair in supine position (WPS), and wedge pair in decubitus position (WPD) techniques. A retrospective review was conducted on breast patients (right breast, n = 10 and left breast, n = 10) who received 10 Gy boost after 50 Gy to whole breast. The treatment plans were generated using an isocentric‐based GsCM technique (a VMAT type planning approach) integrating couch rotational motion at static gantry positions. Static fields for each tangential side were merged using a Matlab® script and delivered automatically within the Varian TruebeamTM STx in Developer Mode application as a VMAT arc (wide‐angular medial and short‐angular lateral arcs). The dosimetric accuracy of the plan delivery was evaluated by ion chamber array measurements in phantom. For both right and left breast boost GsCM, 3D‐CRT, WPS, and WPD all provided an adequate coverage to PTV. GsCM significantly reduced the ipsilateral lung V30% for right side (mean, 80%) and left side (mean, 70%). Heart V5% reduced by 90% (mean) for right and 80% (mean) for left side. Ipsilateral breast V50% and mean dose were comparable for all techniques but for GsCM, V100% reduced by 50% (mean) for right and left side. The automated delivery of both arcs was under 2 min as compared to delivering individual fields (30 ± 5 min). The gamma analysis using 2 mm distance to agreement (DTA) and 2% dose difference (DD) was 98 ± 1.5% for all 20 plans. The GsCM technique facilitates coronal plane dose delivery appropriate for deep‐seated breast boost cavities, with sufficient dose conformity of target volume paired with sparing of the OARs.